Skip Navigation

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
NIH HHS News Release Logo

National Institute of Allergy and
Infectious Diseases (NIAID)

Friday, Jan. 28, 2000

Media Contact:
Greg Folkers
(301) 402-1663

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Newly Updated HIV Treatment Guidelines for Adults and Adolescents Available on the World Wide Web

An updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents has been posted to the HIV/AIDS Treatment Information Service (ATIS) World Wide Web site,

The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection, a joint effort of the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Initially published in 1998, the Guidelines were constructed as a "living document" and are updated frequently by the Panel as new data emerge.

"The number of treatment options for HIV-infected individuals has increased dramatically, making decisions regarding therapy more and more complex," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and co-chair of the Panel. "The new Guidelines, based on the latest available research findings, provide recommendations on how to optimally use the many antiretroviral medications and sophisticated laboratory tests now available to people living with HIV."

The updated Guidelines are available at in two formats, a typeset version (PDF) and a Web version (HTML). Single copies can be ordered by calling 1-800-448-0440 (international callers may call 1-301-519-0459), or by sending an e-mail request to

The updated Guidelines include recommendations for the use in clinical practice of recently developed tests that help determine if the virus a patient is carrying has developed resistance to one or more antiretroviral drugs.

"These tests can help to explain the reasons for treatment failure and guide the rational selection of a new drug regimen," says John G. Bartlett, M.D., chief of the division of infectious diseases at the Johns Hopkins University Medical Center and co-chair of the Panel. "The likelihood of reducing viral load to undetectable levels is significantly increased when results of resistance testing are available to guide the selection of a new drug regimen for patients who are not doing well on their current regimens."

The updated Guidelines also contain a new section entitled "The Goals of Therapy." In addition to reiterating the goal of suppressing plasma viral load to below detectable levels for as long as possible, the Guidelines Panel recognizes that eradication of HIV infection is probably not possible with currently available treatments and emphasizes the need to think strategically about antiretroviral therapy.

In this regard, the updated Guidelines discuss other primary goals of antiretroviral therapy, including --

  • restoration and/or preservation of the patient's immunologic function
  • improvement of their quality of life
  • reduction of HIV-related illness and death.

The new Guidelines also delineate tools that may help achieve these goals, including --

  • maximizing patient adherence to a regimen
  • selecting "user-friendly" regimens when possible
  • prescribing drugs in a rational sequence in order to preserve future treatment options
  • utilizing drug resistance assays when treatment fails.

The Panel also has reorganized its recommendations for the use of antiretroviral drugs in the initial therapy of HIV infection. Previously, drugs were placed in the "Preferred" category on the basis of their ability to suppress plasma viral load. In keeping with the newly elaborated goals of therapy, considerations such as pill burden, dosing frequency, food requirements, convenience, toxicity and drug interaction profiles underpin the new recommendations.

The updated Guidelines' "Strongly Recommended" category now includes a small number of drugs the Panel feels can accomplish many therapeutic goals with minimal negative effects on an HIV-infected individual's quality of life. Other potent drugs that can also suppress plasma viral load but do so at a high cost to quality of life are now included under the heading "Recommended as Alternatives."

Finally, a new hypertext link to detailed information on the use of antiretroviral drugs in pregnant women has been added. This information will help physicians select the most appropriate antiretroviral regimen for their HIV-infected patients who are pregnant.

Co-conveners of the Panel on Clinical Practices for the Treatment of HIV Infection are Eric Goosby, M.D., on behalf of the Department of Health and Human Services, and Jennifer Kates, M.A, M.P.A., on behalf of the Henry J. Kaiser Family Foundation. Oren J. Cohen, M.D., NIAID Assistant Director for Medical Affairs, serves as the Panel's Executive Secretary.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health ®

back to top


NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.

Last Updated January 28, 2000